THE NHS website couldn’t cope with demand, crash-ing under the strain of so many people trying to book their boosters this week. The emergence of the Omicron variant and its timing, in the run-up to Christmas, have fuelled the rush for jabs. But this time around, AstraZeneca is prominent by its absence. The home-grown jab, once hailed by Boris Johnson as “a wonderful British scientific achievement”, was passed over in favour of Pfizer for the booster roll-out, and it looked like a serious snub for the Anglo-Swedish drug company. So what happened? And if AZ is not needed in the UK, could it have a critical role to play in preventing new variants?
“AstraZeneca is destined for lower and middle-income countries now,” explains Professor Azeem Majeed, head of the department of primary care and public health at Imperial College London. “It served us well in the first stage of the vaccine roll-out, but it would take a big shift in government policy to bring it back in the UK.”
The Joint Committee on Vaccination and Immunisation (JCVI) has decided it is not quite as effective as mRNA vaccines — which teach our cells how to make a protein that triggers an immune response — as a booster shot. There have also been concerns about a rare blood-clotting side effect, although today scientists said they believe they have found the “trigger” that leads to this.
This story is from the December 02, 2021 edition of Evening Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the December 02, 2021 edition of Evening Standard.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 8,500+ magazines and newspapers.
Already a subscriber? Sign In
Doing a set on stage, the nerves are a match for playing at the Crucible'
IN one room a female performer is rapping in Spanish as a support band jams behind her, and students gyrate wildly on the dance floor.
Sunak: It's my moral mission to get people back to work
RISHI SUNAK today claimed there was a “moral mission” to end “sick note culture” and get fit people back to work.
BIG BEN JOINS THE GUNNERS TARGETS
CLUB RAMPS UP SPENDING PLANS WITH 6FT 4IN STRIKER SESKO ON LIST
Arteta faces trust issue as he bids to get tired Gunners firing again
MIDNIGHT was turning into the early hours of yesterday morning by the time Arsenal finally left the Allianz Arena after their painful Champions League defeat by Bayern Munich.
For a change, Poch has a shot at having final say against Pep
THERE is no manager Mauricio Pochettino has faced more frequently in his career than Pep Guardiola, and tomorrow's FA Cup semi-final between Chelsea and Manchester City will bring up 25 meetings between the old rivals.
Daring Hammers give Moyes' Euro story one more thrilling chapter
IN THE final moments before kick-off, after an endless stream of rousing montages had finally run its course and as West Ham’s players huddled so long they had to be reminded by the referee’s whistle of a second leg to play, the London Stadium filled the airtime with a passionate chorus of the chant it has claimed as its own with such glee all year. Champions of Europe, we know what we are.
Cairess: I've got big ambitions and the first is to break Mo's record
FOR virtually three-quarters of his marathon debut in London last year, Emile Cairess’s sole thought was how to catch Mo Farah.
Clumsy, jarring, predictable: not vintage Taylor
Defensive lyrics and affecting moments-what El Hunt makes of the Queen of Pop's latest release
It's great Brixton Academy is reopening, but they owe it to London to get it right
MORE than a year after a fatal crush killed two people at the O2 Brixton Academy, the south London gig venue is gearing up for a carefully managed reopening, with a long list of robust safety guidelines now in place.
How did Sydney Sweeney become the most divisive star in Hollywood?
The actress is at the heart of a political tug of war and her breasts are polarising US society. What’s really going on, asks Maddy Mussen